Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.
|Videos|June 15, 2017
Safety Results for Daratumumab Combined With Carfilzomib, Lenalidomide, and Dexamethasone in Multiple Myeloma
Author(s)Andrzej Jakubowiak, MD, PhD
Andrzej Jakubowiak, MD, PhD, professor of Medicine, University of Chicago Medicine, discusses safety results from an open label, phase 1b trial exploring daratumumab (Darzalex) combined with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone in patients with newly diagnosed multiple myeloma.
Advertisement
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.
The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.
Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
As New TGCT Therapies Advance, Route, Duration, and Coverage Shape CSF1R Inhibitor Choice
3
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
4
Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs
5